Confused today, well so are a lot of other folks. As the fields of new and supplemental information become available, it does reach a point to where you are almost forced to choose an area of focus for R and D in particular and this press release pretty much tells the story, something others could be pondering down the road. What will generate money is the primary focus to stay in business and will affiliations with others benefit? I think everyone questions the same thing today as the fields of gray continue to grow. BD
MYGN 65.46, +0.58, +0.9%) today announced that its Board of Directors is reviewing management's analysis of several strategic alternatives for the Company and is carefully considering these alternatives.
"The Board is committed to growing both of our business opportunities in a way that seeks to maximize shareholder value," said John Henderson, Chairman of the Board. "We are continuing our deliberations and intend to announce a decision before the end of the year."
Among the alternatives under consideration, the Board is exploring whether to spin-off the pharmaceutical subsidiary from Myriad's molecular diagnostic business in a transaction that would result in two independent and highly focused businesses.